# US 2022/0241433 A1 · Nerve regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0241433 A1
- Document ID: US20220241433A1
- Status: Published application
- Kind: A1
- Application number: 17/500,832
- Filed: 2021-10-13
- Published: 2022-08-04
- Earliest claimed: 2004-06-23
- Assignees: Kolon Tissuegene, Inc.
- Applicants: Kolon Tissuegene, Inc.
- Inventors: Chang Hwan KIM; Kwan Hee LEE
- Web page: https://patentgrep.com/patent/US20220241433A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/1883: {Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/021: for the expression of a heterologous nucleic acid
- C12N 2799/022: where the vector is derived from an adenovirus
- C12N 2799/025: where the vector is derived from a parvovirus
- C12N 2799/027: where the vector is derived from a retrovirus
- C12N 2799/028: where the vector is derived from a herpesvirus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application describes a method of regenerating nerve, which steps include generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter; transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.

## Claims

### Claim 1

A method of regenerating nerve, comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and
c) transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the transforming growth factor is BMP.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the BMP is BMP-2 and BMP-9.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cell is a connective tissue cell.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the cell is a fibroblast cell.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cell is a nerve cell.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the nerve is peripheral nerve.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the vector is a viral vector.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the vector is retroviral vector, adeno-associated viral vector, adenoviral vector, or herpes viral vector.

### Claim 10 (depends on 1)

The method of claim 1, wherein said population of cells are stored prior to transplantation.

### Claim 11 (depends on 4)

The method of claim 4, wherein said population of transfected ells are stored in 10% DMSO under liquid nitrogen prior to transplantation.

### Claim 12

A method of regenerating nerve, comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a myelin sheath regenerating protein;
b) transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and
c) transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the cell is a connective tissue cell.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the cell is a fibroblast cell.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the cell is a nerve cell.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the cell is a glial cell.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the cell is Schwann cell.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the protein is neuregulin-1.

### Claim 19 (depends on 12)

The method according to claim 12, wherein the nerve is peripheral nerve.
